Skip to main content
  • Intracoronary Abciximab Better for Diabetics? Meta-analysis suggests big advantage, but some call it implausible

    For patients with diabetes, abciximab (Reopro) was best given straight to the heart during primary percutaneous coronary intervention (PCI) after ST-segment elevation MI (STEMI), a meta-analysis suggested.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details